Oral pentoxifylline combined with pentavalent antimony: A randomized trial for mucosal leishmaniasis

Paulo R L Machado, Hélio Lassa, Marcus Lessa, Luiz H. Guimarǎes, Heejung Bang, John L. Ho, Edgar M. Carvalho

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

Background. Mucosal leishmaniasis is associated with intense tissue damage and high tumor necrosis factor-α production. Therapeutic failure occurs in up to 42% of cases; patients who experience treatment failure will require >1 pentavalent antimony (Sbv) course or alternative drugs to achieve a cure. We previously showed that an inhibitor of tumor necrosis factor-α (pentoxifylline) combined with Sbv cured 90% patients refractory to monotherapy with Sbv. Methods. A double-blind, placebo-controlled trial involving 23 patients with mucosal leishmaniasis evaluated the efficacy of pentoxifylline when administered in association with Sbv, compared with Sbv treatment alone. Eleven patients were randomized to receive Sbv plus oral pentoxifylline for 30 days, and 12 patients received Sbv plus oral placebo. The criterion for cure was a complete healing of lesions. Results. All patients in the pentoxifylline group experienced a cure with 1 course of Sbv, whereas 5 (41.6%) of 12 patients in the placebo group required a second course of Sbv (P = .037). The healing time ± standard deviation in the pentoxifylline group was 83 ± 36 days, compared with 145 ± 99 days in the placebo group (P = .049). No relapses were documented in either group at the 2-year follow-up visit. Conclusions. The addition of pentoxifylline to Sbv in mucosal leishmaniasis reduces the healing time significantly and prevents the need for further courses of Sbv.

Original languageEnglish (US)
Pages (from-to)788-793
Number of pages6
JournalClinical Infectious Diseases
Volume44
Issue number6
DOIs
StatePublished - Mar 15 2007
Externally publishedYes

Fingerprint

Antimony
Pentoxifylline
Leishmaniasis
Placebos
Tumor Necrosis Factor-alpha
Treatment Failure
Recurrence
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Immunology

Cite this

Machado, P. R. L., Lassa, H., Lessa, M., Guimarǎes, L. H., Bang, H., Ho, J. L., & Carvalho, E. M. (2007). Oral pentoxifylline combined with pentavalent antimony: A randomized trial for mucosal leishmaniasis. Clinical Infectious Diseases, 44(6), 788-793. https://doi.org/10.1086/511643

Oral pentoxifylline combined with pentavalent antimony : A randomized trial for mucosal leishmaniasis. / Machado, Paulo R L; Lassa, Hélio; Lessa, Marcus; Guimarǎes, Luiz H.; Bang, Heejung; Ho, John L.; Carvalho, Edgar M.

In: Clinical Infectious Diseases, Vol. 44, No. 6, 15.03.2007, p. 788-793.

Research output: Contribution to journalArticle

Machado, PRL, Lassa, H, Lessa, M, Guimarǎes, LH, Bang, H, Ho, JL & Carvalho, EM 2007, 'Oral pentoxifylline combined with pentavalent antimony: A randomized trial for mucosal leishmaniasis', Clinical Infectious Diseases, vol. 44, no. 6, pp. 788-793. https://doi.org/10.1086/511643
Machado, Paulo R L ; Lassa, Hélio ; Lessa, Marcus ; Guimarǎes, Luiz H. ; Bang, Heejung ; Ho, John L. ; Carvalho, Edgar M. / Oral pentoxifylline combined with pentavalent antimony : A randomized trial for mucosal leishmaniasis. In: Clinical Infectious Diseases. 2007 ; Vol. 44, No. 6. pp. 788-793.
@article{6251f7c83e684b3781832a4f2a7def32,
title = "Oral pentoxifylline combined with pentavalent antimony: A randomized trial for mucosal leishmaniasis",
abstract = "Background. Mucosal leishmaniasis is associated with intense tissue damage and high tumor necrosis factor-α production. Therapeutic failure occurs in up to 42{\%} of cases; patients who experience treatment failure will require >1 pentavalent antimony (Sbv) course or alternative drugs to achieve a cure. We previously showed that an inhibitor of tumor necrosis factor-α (pentoxifylline) combined with Sbv cured 90{\%} patients refractory to monotherapy with Sbv. Methods. A double-blind, placebo-controlled trial involving 23 patients with mucosal leishmaniasis evaluated the efficacy of pentoxifylline when administered in association with Sbv, compared with Sbv treatment alone. Eleven patients were randomized to receive Sbv plus oral pentoxifylline for 30 days, and 12 patients received Sbv plus oral placebo. The criterion for cure was a complete healing of lesions. Results. All patients in the pentoxifylline group experienced a cure with 1 course of Sbv, whereas 5 (41.6{\%}) of 12 patients in the placebo group required a second course of Sbv (P = .037). The healing time ± standard deviation in the pentoxifylline group was 83 ± 36 days, compared with 145 ± 99 days in the placebo group (P = .049). No relapses were documented in either group at the 2-year follow-up visit. Conclusions. The addition of pentoxifylline to Sbv in mucosal leishmaniasis reduces the healing time significantly and prevents the need for further courses of Sbv.",
author = "Machado, {Paulo R L} and H{\'e}lio Lassa and Marcus Lessa and Guimarǎes, {Luiz H.} and Heejung Bang and Ho, {John L.} and Carvalho, {Edgar M.}",
year = "2007",
month = "3",
day = "15",
doi = "10.1086/511643",
language = "English (US)",
volume = "44",
pages = "788--793",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Oral pentoxifylline combined with pentavalent antimony

T2 - A randomized trial for mucosal leishmaniasis

AU - Machado, Paulo R L

AU - Lassa, Hélio

AU - Lessa, Marcus

AU - Guimarǎes, Luiz H.

AU - Bang, Heejung

AU - Ho, John L.

AU - Carvalho, Edgar M.

PY - 2007/3/15

Y1 - 2007/3/15

N2 - Background. Mucosal leishmaniasis is associated with intense tissue damage and high tumor necrosis factor-α production. Therapeutic failure occurs in up to 42% of cases; patients who experience treatment failure will require >1 pentavalent antimony (Sbv) course or alternative drugs to achieve a cure. We previously showed that an inhibitor of tumor necrosis factor-α (pentoxifylline) combined with Sbv cured 90% patients refractory to monotherapy with Sbv. Methods. A double-blind, placebo-controlled trial involving 23 patients with mucosal leishmaniasis evaluated the efficacy of pentoxifylline when administered in association with Sbv, compared with Sbv treatment alone. Eleven patients were randomized to receive Sbv plus oral pentoxifylline for 30 days, and 12 patients received Sbv plus oral placebo. The criterion for cure was a complete healing of lesions. Results. All patients in the pentoxifylline group experienced a cure with 1 course of Sbv, whereas 5 (41.6%) of 12 patients in the placebo group required a second course of Sbv (P = .037). The healing time ± standard deviation in the pentoxifylline group was 83 ± 36 days, compared with 145 ± 99 days in the placebo group (P = .049). No relapses were documented in either group at the 2-year follow-up visit. Conclusions. The addition of pentoxifylline to Sbv in mucosal leishmaniasis reduces the healing time significantly and prevents the need for further courses of Sbv.

AB - Background. Mucosal leishmaniasis is associated with intense tissue damage and high tumor necrosis factor-α production. Therapeutic failure occurs in up to 42% of cases; patients who experience treatment failure will require >1 pentavalent antimony (Sbv) course or alternative drugs to achieve a cure. We previously showed that an inhibitor of tumor necrosis factor-α (pentoxifylline) combined with Sbv cured 90% patients refractory to monotherapy with Sbv. Methods. A double-blind, placebo-controlled trial involving 23 patients with mucosal leishmaniasis evaluated the efficacy of pentoxifylline when administered in association with Sbv, compared with Sbv treatment alone. Eleven patients were randomized to receive Sbv plus oral pentoxifylline for 30 days, and 12 patients received Sbv plus oral placebo. The criterion for cure was a complete healing of lesions. Results. All patients in the pentoxifylline group experienced a cure with 1 course of Sbv, whereas 5 (41.6%) of 12 patients in the placebo group required a second course of Sbv (P = .037). The healing time ± standard deviation in the pentoxifylline group was 83 ± 36 days, compared with 145 ± 99 days in the placebo group (P = .049). No relapses were documented in either group at the 2-year follow-up visit. Conclusions. The addition of pentoxifylline to Sbv in mucosal leishmaniasis reduces the healing time significantly and prevents the need for further courses of Sbv.

UR - http://www.scopus.com/inward/record.url?scp=33847625958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847625958&partnerID=8YFLogxK

U2 - 10.1086/511643

DO - 10.1086/511643

M3 - Article

C2 - 17304449

AN - SCOPUS:33847625958

VL - 44

SP - 788

EP - 793

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 6

ER -